OGX5 28
Alternative Names: OGX5-28Latest Information Update: 05 Sep 2023
At a glance
- Originator OsteoGenex
- Class Small molecules
- Mechanism of Action SOST protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Osteoporosis
Most Recent Events
- 05 Sep 2023 Discontinued - Preclinical for Osteoporosis in USA (PO)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Osteoporosis in USA (PO)